There have been almost 50,000 cases of RSV recorded this year, but only a select group can access the free vaccine, with ...

Against the backdrop of World Immunization Week, Dr Reddy’s Laboratories Ltd and Sanofi Healthcare India have expanded their partnership to bring in Beyfortus – a novel drug to prevent ...

Overall, 72% of 36,949 infants were immunized in the 2023-2024 RSV season with either the bivalent RSV prefusion F protein ...

The American Academy of Pediatrics has said childhood vaccines are carefully studied in randomized controlled trials — ...

Dr Reddy’s Laboratories expands its strategic partnership with Sanofi Healthcare India to introduce a novel drug, Beyfortus (nirsevimab), in India. Beyfortus contains the monoclonal antibody, ...

We came across a bullish thesis on Sanofi (SNY) on Substack by Business Model Mastery. In this article, we will summarize the ...

France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug Dupixent, as well as newer treatments and vaccines.

The data suggest that the most severe RSV disease among infants up to seven months old is preventable, the CDC said, adding that it is important to protect infants, ideally within ...

Far fewer babies had severe cases of the respiratory illness RSV, in a winter in which a new monoclonal and vaccine became ...

Dr. Reddy’s Laboratories will expand its partnership with Sanofi Healthcare India (SHIPL) by launching the latter’s novel drug Beyfortus (nirsevimab) in India. Containing monoclonal antibody ...

It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...